Drug Combination Details
| General Information of the Combination (ID: C57932) | |||||
|---|---|---|---|---|---|
| Name | Honokiol NP Info | + | Rosiglitazone Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCNE1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RB1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Mahlavu | CVCL_0405 | Hepatocellular carcinoma | Homo sapiens | ||
| SK-HEP-1 | CVCL_0525 | Hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells. J Chin Med Assoc. 2016 Aug;79(8):415-21. | |||
